This site is intended for healthcare professionals
News

FDA approves Cortrophin Gel for acute flare-ups in multiple sclerosis and other autoimmune conditions.

Read time: 1 mins
Published:10th Nov 2021
The injectable ACTH gel medication Cortrophin Gel (repository corticotropin injection), first introduced in the U.S. in the 1950s, will now be relaunched by ANI Pharmaceuticals as a treatment for acute flare-ups in multiple sclerosis (MS) and other autoimmune conditions, following its approval by the FDA.

In addition to MS, the FDA has now approved Cortrophin Gel for indications that include acute exacerbations from rheumatoid arthritis, and excess protein in the urine due to nephrotic syndrome. ANI Pharmaceuticals is planning a full-scale commercial launch of Cortrophin Gel in early first-quarter 2022.

Condition: AutoImmune Diseases
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.